Table 1 Characteristics of individual studies included in the meta-analysis
From: Associations of the APOC3 rs5128 polymorphism with plasma APOC3 and lipid levels: a meta-analysis
First author, reference | year | Ethnicity | Gender | Study population | Outcomes |
|---|---|---|---|---|---|
Aburatani [11] | 1988 | Asian | M/F | Subjects with hyperlipidemia and controls | APOC3, TG, TC, HDL-C |
Paulweber1 [12] | 1988 | Caucasian | M | Patients with CVD | TG |
Paulweber2 [12] | 1988 | Caucasian | M | Subjects without CVD | TG |
Ahn [13] | 1991 | Other | M/F | Random subjects | APOC3, TG, TC |
Shoulders1 [14] | 1991 | Caucasian | M | Healthy subjects | APOC3 |
Shoulders2 [14] | 1991 | Caucasian | F | Healthy subjects | APOC3 |
Ordovas1 [15] | 1991 | Caucasian | M/F | Patients with CVD | TG, TC, HDL-C |
Ordovas2 [15] | 1991 | Caucasian | M/F | Healthy population | TG, TC, HDL-C |
Tybjaerg-Hansen1 [16] | 1993 | Caucasian | M | Subjects with CVD | TG, HDL-C |
Tybjaerg-Hansen2 [16] | 1993 | Caucasian | M | Subjects without CVD | TG, HDL-C |
Miettinen1 [17] | 1994 | Caucasian | M/F | Subjects with CVD | TG, TC, LDL-C, HDL-C |
Miettinen2 [17] | 1994 | Caucasian | M/F | Subjects without CVD | TG, TC, LDL-C, HDL-C |
Rigoli [18] | 1995 | Caucasian | M/F | Patients with type 2 diabetes | TG, TC, LDL-C, HDL-C |
Bai1 [19] | 1995 | Asian | M/F | Subjects with CVD | APOC3, TG, TC, HDL-C |
Bai2 [19] | 1995 | Asian | M/F | Subjects without CVD | APOC3, TG, TC, HDL-C |
Shoulders [20] | 1996 | Caucasian | M/F | Random healthy children | APOC3, TG |
López-Miranda [21] | 1997 | Caucasian | M | Random healthy youth | TG, TC, LDL-C, HDL-C |
Kee [22] | 1999 | Caucasian | M | Random subjects | APOC3, TG, TC, LDL-C, HDL-C |
Dallongeville1 [23] | 2000 | Caucasian | M | Random subjects | APOC3, TG, TC, LDL-C, HDL-C |
Dallongeville2 [23] | 2000 | Caucasian | F | Random subjects | APOC3, TG, TC, LDL-C, HDL-C |
Wu [24] | 2000 | Asian | M/F | Random subjects without CVD | APOC3, TG, TC, LDL-C, HDL-C |
Waterworth1 [25] | 2000 | Caucasian | M/F | Non-smokers | TG |
Waterworth2 [25] | 2000 | Caucasian | M/F | Exsmokers (cessation for minimum of 1Â year) | TG |
Waterworth3 [25] | 2000 | Caucasian | M/F | Current smokers | TG |
Russo1 [26] | 2001 | Caucasian | M | Framingham Offspring Study | APOC3, TG, TC, LDL-C, HDL-C |
Russo2 [26] | 2001 | Caucasian | F | Framingham Offspring Study | APOC3, TG, TC, LDL-C, HDL-C |
Olivieri [27] | 2002 | Caucasian | M/F | Subjects with or without CVD | APOC3, TG |
Corella1 [28] | 2002 | Caucasian | M | Random healthy subjects | TG, TC, LDL-C, HDL-C |
Corella2 [28] | 2002 | Caucasian | F | Random healthy subjects | TG, TC, LDL-C, HDL-C |
Rodrigo1 [29] | 2002 | Caucasian | M | Patients undergoing kidney transplantation | TG, TC |
Rodrigo2 [29] | 2002 | Caucasian | F | Patients undergoing kidney transplantation | TG, TC |
Couillard [30] | 2003 | Caucasian | M | Abdominally obese subjects | APOC3, TG, TC, LDL-C, HDL-C |
Brown [31] | 2003 | Other | M/F | Random subjects | TG, TC, LDL-C, HDL-C |
Espino-Montoro [32] | 2003 | Caucasian | M/F | Hypertensive patients | TG, TC, LDL-C, HDL-C |
Chen [33] | 2004 | Asian | M/F | Patients with type 2 diabetes | APOC3, TG, TC, LDL-C, HDL-C |
Chhabra1 [34] | 2004 | Asian | M/F | Patients with CVD | TG, TC, LDL-C, HDL-C |
Chhabra2 [34] | 2004 | Asian | M/F | Subjects without CVD | TG, TC, LDL-C, HDL-C |
Liu1 [35] | 2004 | Caucasian | M | Subjects with CVD | TG, TC, HDL-C |
Liu2 [35] | 2004 | Caucasian | M | Subjects without CVD | TG, TC, HDL-C |
de França1 [36] | 2005 | Other | M | Healthy children | TG, TC, LDL-C, HDL-C |
de França2 [36] | 2005 | Other | F | Healthy children | TG, TC, LDL-C, HDL-C |
Arai1 [37] | 2005 | Asian | M | Random subjects | TG, LDL-C, HDL-C |
Arai2 [37] | 2005 | Asian | F | Random subjects | TG, LDL-C, HDL-C |
Liu1 [38] | 2005 | Asian | M/F | Patients with CVD | TG, TC, LDL-C, HDL-C |
Liu2 [38] | 2005 | Asian | M/F | Patients with type 2 diabetes | TG, TC, LDL-C, HDL-C |
Liu3 [38] | 2005 | Asian | M/F | Subjects without CVD and type 2 diabetes | TG, TC, LDL-C, HDL-C |
Islam [39] | 2005 | Caucasian | M/F | Random subjects | TG, TC, LDL-C, HDL-C |
Stancáková [40] | 2006 | Caucasian | M/F | Patients with dyslipidemia of metabolic syndrome | TC, LDL-C, HDL-C |
Herron [41] | 2006 | Caucasian | M/F | Random subjects | APOC3, TG, LDL-C, HDL-C |
Huang [42] | 2006 | Asian | M/F | Subjects with hypertriglyceridemia or normal | APOC3, TG |
Fiegenbaum1 [43] | 2007 | Caucasian | M | Random healthy subjects | TG, HDL-C |
Fiegenbaum2 [43] | 2007 | Caucasian | F | Random healthy subjects | TG, HDL-C |
Nieminen [44] | 2007 | Caucasian | M/F | Random youth | TG, TC, LDL-C, HDL-C |
Parzianello1 [45] | 2008 | Asian | M/F | Subjects with hypertriglyceridemia | TG, TC, LDL-C, HDL-C |
Parzianello2 [45] | 2008 | Asian | M/F | Subjects free of hypertriglyceridemia | TG, TC, LDL-C, HDL-C |
Dallongeville [46] | 2008 | Caucasian | M/F | Random subjects | TG, HDL-C |
Ruiz1 [47] | 2008 | Caucasian | M | Random healthy children | TG, TC, LDL-C, HDL-C |
Ruiz2 [47] | 2008 | Caucasian | F | Random healthy children | TG, TC, LDL-C, HDL-C |
Smith1 [48] | 2009 | Caucasian | M/F | Patients with type 2 diabetes | TG, TC, LDL-C, HDL-C |
Smith2 [48] | 2009 | Caucasian | M/F | Subjects free of type 2 diabetes | TG, TC, LDL-C, HDL-C |
Yiyang1 [49] | 2010 | Asian | M/F | Random subjects | TG, TC, LDL-C, HDL-C |
Yiyang2 [49] | 2010 | Asian | M/F | Random subjects | TG, TC, LDL-C, HDL-C |
Sediri1 [50] | 2011 | Other | M | Males with CVD | TG, TC, LDL-C, HDL-C |
Sediri2 [50] | 2011 | Other | M | Males without CVD | TG, TC, LDL-C, HDL-C |
Abd El-Aziz3 [51] | 2011 | Other | M/F | Patients with CVD and controls | TG, TC, LDL-C, HDL-C |
Bandegi1 [52] | 2011 | Other | M/F | Subjects with primary hyperlipidemia | TG, TC, LDL-C, HDL-C |
Bandegi2 [52] | 2011 | Other | M/F | Normolipidemic subjects | TG, TC, LDL-C, HDL-C |